Severe acute respiratory syndrome (SARS) is a disease that has newly emerged in the 21st century, and is both severe and highly contagious. SARS first surfaced in late 2002 and spread within a few months from its origin in Guandong province, China, to more than 30 countries (World Health Organization, 2003). In this review, several antiviral substances shown to be active in vitro will be introduced and summarized in the order of the virus' replication steps; that is, binding to cellular receptor, fusion and entry to the cells, viral RNA replication and transcription, protein processing and so on. The possible clinical use of several synthetic peptides, including those that mimic the S-binding domain, the HR2 fusion protein and SARS proteinase substrates, will be discussed. Monoclonal antibodies (Mabs) and established drugs, such as interferons and HIV proteinase inhibitors, are also discussed in relation to anti-SARS clinical use.
AnandKZiebuhrJWadhwaniPMestersJR & HilgenfeldR (2003) Coronavirus main proteinase (3CLpro) structure: Basis for design of anti SARS drugs. Science300: 1763–1767.
2.
AntonelliGScagnolariCVicenziE & ClementiM (2003) Treatment of SARS with human interferons. Lancet362: 1158–1159.
3.
BarnardDLHubbardVDBurtonJSmeeDFMorreyJDOttoMJ & SidwellRW (2004) Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS CoV) by calpain inhibitors and beta-D-N4-hydoxycytidine. Antiviral Chemistry & Chemotherapy15: 15–22.
4.
BartenschlagerR (2002) Hepatitis C virus replicons: Potential role for drug development. National Review of Drug Discovery1: 911–916.
5.
BerryJDJonesSDrebotMAAndonovASabaraMYuanXYWeingartlHFernandoLMarszalPGrenJNicolasBAndonovaMRanadaFGubbinsMJBallTBKitchingPLiYKabaniA & PlummerF (2004) Development and characterization of neutralising monoclonal antibody to the SARS-coronavirus. Journal of Virological Methods120: 87–96.
6.
BoothCMMatukasLMTomlinsonGARachlisARRoseDBDwoshHAWalmsleySLMazzulliTAvendanoMDerkashPEphtimiosIEKitaiIMederskiBDShadowitzSBGoldWLHawrylackLAReaEChenkinJSCesconDWPoutanenSM & DetskeyAS (2003) Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. Journal of the American Medical Association289: 2801–2809.
7.
ChengPKCWangDATongLKLMingSIpSLoACTLauC-SYuengEYH & LimWWL (2004) Viral shedding patterns of coronavrus in patients with probable severe acute respiratory syndrome. Lancet363: 1699–1700.
8.
ChouK-CWeiD-Q & ZhongW-Z (2003) Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochemical & Biophysical Research Communications308: 148–151.
9.
ChuCMChengVCCHungIFNWongMMLChanKHChanKSKaoRYTPoonLLMWongCLPGuanYPeirisJSM & YuenKY (2004) Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax59: 252–256.
10.
CinatlJMorgensternBBauerGChandraPRabenauH & DoerrH (2003a) Treatment of SARS with human interferons. Lancet362: 293–294.
11.
CinatlJMorgensternBBauerGChandraPRabenauH & DoerrH (2003b) Glycyrrhizin, an active component of liquorice roots, and replication of SARS associated coronavirus. Lancet361: 2045–2046.
12.
De ClercqE (1985) Antiviral and antimetabolic activities of neplanocins. Antimicrobial Agents & Chemotherapy28: 84–89.
13.
DemmllerGL & LigonBL (2003) Severe acute respiratory syndrome (SARS): A review of history, epidemiology, prevention, and concerns for the future. Seminar of Pediatric Infectious Diseases14: 240–244.
14.
EnserinkM (2004) Interferon shows promise in monkeys. Science303: 1273–1274.
15.
FanKWeiQFengSChenCHuangLLaiMBPeiJLiuYChenJ & LaiL (2004) Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. Journal of Biological Chemistry279: 1637–1642.
16.
HattoriTIkematsuSKoitoAMatsushitaSMaedaYHadaMFujimakiM & TakatsuskiK (1989) Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS. Antiviral Research11: 255–262.
17.
HeRAdonovATrakova-AdonovaMCaoJCuttsTGrudeskyEDeschambaulYBerryJDrevotM & LiX (2004) Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochemical & Biophysical Research Communications320: 1199–1203.
HertzigTScandellaESchelleBZiebuhrJSiddellSGLudewigB & ThielV (2004) Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. Journal of General Virology85: 1717–1725.
20.
HoffmanHGeierMMarziAKrumbiegelMPeippMFeyGHGrambergT & PohlmanS (2004) Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochemical & Biophysical Research Communications319: 1216–1221.
21.
ItoMSatoAHirabayashiKTanabeFShigetaSBabaMDe ClercqENakashimaH & YamamotoN (1988) Mechanisms of inhibitory effect of glycyrrizin on replication of human immunodeficiency virus (HIV). Antiviral Research10: 289–298.
22.
JenwitheesukE & SamudralaR (2003) Identifying inhibitors of the SARS coronavirus proteinase. Bioorganic Medicinal Chemistry Letters13: 3989–3992.
23.
JeongHG & KimJY (2002) Induction of inducible nitric oxide synthetase expression by 18b glycyrrhetinic acid in macrophages. FEBS Letters513: 208–212.
24.
KeyaertsEVijgenLChenLMaesPHedenstiernaG & RanstMV (2004) Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. International Journal of Infectious Diseases8: 223–226.
25.
KuoC-JChiY-HHsuJT-A & LiangP-H (2004) Characterization of SARS main protease and inhibitor assay using fluorogenic substrate. Biochemical & Biophysical Research Communications318: 862–867.
26.
La MomtagneJRSimonsenLTaylorRJ, Turnbull J & SARS Working Group (2004) Severe acute respiratory syndrome: Developing a research response. Journal of Infectious Diseases189: 634–641.
27.
LaiMMC & HolmesKV (2001) Coronaviridae: The viruses and their replication. In Fields' Virology, 4th ed.Philadelphia: Lippincott-Williams & Wilkins, pp. 1163–1185.
28.
LiWMooreMJVasilievaNSuiJWongSKBerneMASomasundaranMSullivanJLLuzuriagaKGreenoughTCChoeH & FarzanM (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature426: 450–454.
29.
LiuSXiaoGChenYHeYNiuJEscalanteCRXiongHFarmarJDebnathAKTienP & JiangS (2004) Interaction between hepted repeat 1 and 2 region in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet363: 938–947.
30.
LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHPhamDHDeifHLaMereEAChangMKainKCFarcasGAFergusonPLatchfoldMLevyGDennisJWLaiEKY & FishEN (2003) Interferon alfacon-1 plus corticostroids in severe acute respiratory syndrome. Journal of American Medical Associations290: 3222–3228.
31.
ManochaSWalleyKR & RusselJA (2003) Severe acute respiratory distress syndrome (SARS): A critical care perspective. Critical Care Medicine31: 2684–2692.
32.
PeirisJSMLaiSTPoonLLMGuanYYamLYCLimWNichollsJYeeWKSYanWWChengMT & ChengVCC (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet361: 1319–1325.
33.
ShigetaSMoriSKodamaEKodamaJTakahashiK & YamaseT (2003) Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. Antiviral Research58: 265–271.
34.
SoLK-YLauACWYamLYCCheungTMTPoonEYungRWH & YuenKY (2003) Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet361: 1615–1617.
35.
StroeherUDiCaroALiYStrongJEAokiFPlummerFJonesSM & FeldmannH (2004) Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. Journal of Infectious Diseases189: 1164–1167.
36.
ter MeulenJBakkerABHvan den BrinkENWeveringGJMartinaBEEHaagmansBLKuikenTde KruifJPreiseWSpaanWGelderblomHRGoudsmitJ & OsterhausADME (2004) Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet363: 2139–2141.
37.
TsangKW & LamWK (2003) Management of severe acute respiratory syndrome. American Journal of Respiratory Critical Care Medicine168: 417–424.
38.
TsangKW & SetoW-H (2004) Severe acute respiratory syndrome: Scientific and anecdotal evidence for drug treatment. Current Opinion in Investigational Drugs5: 179–185.
39.
UtsunomiyaTKobayashiMPollardRB & SuzukiF (1997) Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal dose of influenza virus. Antimicrobial Agents & Chemotherapy41: 551–556.
40.
Von GrotthussMWyrwiczLS & RychlewskiL (2003) mRNA cap-1 methyltransferase in the SARS genome. Cell113: 701–702.
41.
WildCOasTMcDanelCBolognesiD & MatthewsT (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proceedings of National Academy of Science, USA89: 10537–10541.
42.
WuG-YJanJ-TMaS-HKuoC-JJuanH-FChengY-SEHsuH-HHungH-CWuDBrikALiangF-SLiuR-SFangJ-MChenS-TLiangP-H & WongC-H (2004) Small molecules targeting severe acute respiratory syndrome human coronavirus. Proceedings of National Academy of Science, USA101: 10012–10017.
43.
WuX & GuarinoLA (2003) Autographa californica nucleopolyhedrovirus orf69 encodes an RNA cap (nucleoside-2′-O)-methyltransferase. Journal of Virology77: 3430–3440.
44.
XuXLiuYWeissSArnoldESarafianosSG & DingJ (2003) Molecular model of SARS coronavirus polymerase: Implications for biochemical functions and drug design. Nucleic Acids Research31: 7117–7130.
45.
YamamotoNYangRYoshinakaYAmariSNakanoTCinatlJRabenauHDoerrHWHunsmannGOtakaATamamuraHFjiiN & YamamotoN (2004) HIV protease inhibitor nelfinavir inhibits replication of SARS associated coronavirus. Biochemical & Biophysical Research Communications318: 719–725.
46.
YountBCurtisKMFritzEAHensleyLEJahrlingPBPrenticeEDenisonMRGiesbertTW & BaricRS (2003) Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proceedings of National Academy of Science, USA100: 12995–13000.
47.
ZhangHWangGLiJNieYShiXLianGWangWYinXZhaoYQuXDingM & DengH (2004) Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. Journal of Virology78: 6938–6945.
48.
ZhuJXiaoGXuYYuanFZhengCLiuYYanHColeDKBellJIRaoZTienP & GaoGF (2004) Following the rule: Formation of the 6 helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochemical & Biophysical Research Communications319: 283–288.
